OTLK · Outlook Therapeutics, Inc.

NasdaqHealthcareBiotechnology

Outlook Therapeutics Inc Is A Clinical-Stage Biopharmaceutical Company Focused On Developing And Commercializing Ons-5010, A Monoclonal Antibody, Or Mab, For Various Ophthalmic Indications. The Company Have Received Marketing Authorization For An Ophthalmic Formulation Of Ons-5010/Lytenava (Bevacizumab-Gamma) For Use In Treating Wet Age-Related Macular Degeneration, Or Wet Amd, In The European Union, And United Kingdom. The Product Pipeline Includes Ons-5010/Lytenava, Which Is In Total Eight Norses; Ons-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-Vegf, And Potential First Line Therapy.

HealthcareNasdaqUS

FLOAT

83.0M

FREE FLOAT %

34%

SHARES O/S

243.4M

MARKET CAP

$126.4M

EXCHANGE

Nasdaq

COUNTRY

OTLK Catalyst History

No catalysts recorded for OTLK yet

Day Trader Sniper hasn't classified a publishable catalyst for OTLK yet. New events appear here as they're scored.

Be early on the next OTLK spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

OTLK · Outlook Therapeutics, Inc.

OTLK Catalyst History

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.